Eli Lilly India gets approval for emergency use of its antibody drugs against COVID-19
Eli Lilly and Company India on Tuesday said it has received emergency use approval of its antibody drugs combination — bamlanivimab 700 mg and etesevimab 1400 mg — used for the treatment of mild to moderate COVID-19 cases in the country.
Luca Visini, Managing Director, India Subcontinent, Lilly, said that "Eli Lilly gets Drugs Controller General of India (DCGI) emergency use approval for its monoclonal antibodies bamlanivimab 700 mg and etesevimab 1400 mg, in India for the treatment of moderate COVID-19 cases."
Also Read | Coronavirus India Updates: Myths and Facts of COVID-19 vaccination; here is what PM Modi govt doing to vaccinate Indians
The company said in a statement that Lilly has been engaging in active dialogue with the Government of India and regulatory authorities to donate bamlanivimab and etesevimab in an order to boost up access and provide treatment for patients with COVID-19.
Also Read | Third wave of coronavirus in Maharashtra? Over 8,000 children test positive in 1 district
The drugs combination has been authorised under the Emergency Use Authorisation in the United States and selected EU countries for the treatment of the disease.
Eli Lilly and Company India MD Luca Visini said that they were pleased that they have another innovative treatment option to offer India's healthcare providers. India has been at the forefront of the battle against coronavirus.
Earlier in May, Eli Lilly had received permission for the emergency use of baricitinib in combination with Remdesivir.
Click here to follow PTC News on Twitter
-PTC News
